• Pomerantz LLP investigates Sarepta Therapeutics for potential securities fraud linked to its Duchenne muscular dystrophy drug, Elevidys, after two patient fatalities.
• Significant stock price declines were observed following the disclosure of patient fatalities, with a notable drop of $27.81 per share after the first incident.
• Analyst ratings and market response vary, with Cowen & Co. downgrading Sarepta from "Buy" to "Hold," and Wells Fargo adjusting its price target amidst ongoing uncertainty.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is under scrutiny as Pomerantz LLP investigates potential securities fraud or unlawful business practices. This investigation is linked to Sarepta's Duchenne muscular dystrophy drug, Elevidys, following two patient fatalities due to acute liver failure. The first incident, disclosed on March 18, 2025, led to a sharp stock price decline of $27.81 per share, or 27.44%, closing at $73.54.

The situation worsened on June 16, 2025, when Sarepta reported a second fatality, prompting the company to halt its clinical trial and suspend Elevidys distribution for non-ambulatory patients. This announcement caused another significant stock drop of $15.24 per share, or 42.12%, closing at $20.94. These events have raised concerns among investors and analysts alike.

In response to these developments, Cowen & Co. downgraded Sarepta from a "Buy" to a "Hold" rating on June 18, 2025, when the stock was priced at $20.77, as highlighted by TheFly. Meanwhile, Wells Fargo maintained its "Overweight" rating but adjusted the price target from $100 to $75, reflecting the ongoing uncertainty surrounding the company.

Currently, SRPT's stock is priced at $19.25, marking a 4.13% decrease with a $0.83 change. The stock has fluctuated between $18.70 and $19.76 today, with a 52-week high of $168.31 and a low of $18.30. Sarepta's market capitalization is approximately $1.89 billion, with a trading volume of 4,203,125 shares on the NASDAQ.